By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
24x7Report24x7Report
  • Home
  • World News
  • Finance
  • Sports
  • Beauty
  • Fashion
  • Fitness
  • Gadgets
  • Travel
Search
© 2023 News.24x7report.com - All Rights Reserved.
Reading: Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating
Share
Aa
24x7Report24x7Report
Aa
Search
  • Home
  • World News
  • Finance
  • Sports
  • Beauty
  • Fashion
  • Fitness
  • Gadgets
  • Travel
  • en English
    • en English
    • id Indonesian
    • ms Malay
    • es Spanish
Follow US
© 2023 News.24x7report.com - All Rights Reserved.
24x7Report > Blog > Finance > Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating
Finance

Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

Last updated: 2026/02/23 at 12:11 AM
Share
3 Min Read
Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating
SHARE

IQVIA Holdings Inc. (NYSE:IQV) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. On February 11, 2026, Morgan Stanley lowered its price target on IQVIA Holdings Inc. (NYSE:IQV) to $240 from $265 but still maintained an Overweight rating, updating its estimates after the company’s quarterly results.

On February 10, 2026, IQVIA Holdings Inc. (NYSE:IQV) and the Duke Clinical Research Institute announced a collaboration aimed at advancing clinical research in obesity and related cardiometabolic trials. Chief Medical and Scientific Officer Jeffrey Spaeder said the partnership is designed to “set a new standard for prospective collaboration” between life science service companies and academic research organizations, with a focus on accelerating clinical trial planning and delivery. The companies said the combined capabilities are intended to improve trial efficiency and speed timelines for bringing therapies to patients.

IQVIA reported fourth-quarter revenue of $4.36 billion on February 5, 2026, above the $4.08 billion consensus estimate. CEO Ari Bousbib said the company closed 2025 with strong performance across all segments, delivering near double-digit revenue and EPS growth, along with its strongest quarter of the year in R&DS net bookings. He added that expanded go-to-market efforts, operational discipline, and AI-related investments supported topline growth across both commercial and clinical businesses, positioning the company for 2026.

Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating
Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

Copyright: dolgachov / 123RF Stock Photo

IQVIA Holdings Inc. (NYSE:IQV) provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.

See also  Apple iPhone 17: Release Date, Price & Specs Rumours

While we acknowledge the potential of IQV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.

You Might Also Like

Wells Fargo Raises its Price Target on The Clorox Company (CLX) to $125 and Maintains an Equal Weight Rating

Michael Burry Says He ‘Slept’ on Bitcoin After Early 2013 Buying Opportunity

Massive blizzard Hernando could slam Wall Street Monday

Pagaya Technologies (PGY) to Exhibit Growth Amid Credit Tightening

UBS Raises its Price Target on Ross Stores, Inc. (ROST) to $199 and Maintains a Neutral Rating

TAGGED: Holdings, IQV, IQVIA, lowers, Maintains, Morgan, Overweight, price, Rating, Stanley, target

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
[mc4wp_form]
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share this Article
Facebook Twitter Copy Link Print
Previous Article Arsenal return to winning ways with win at Spurs in North London Derby
Next Article Dozens of avalanches reported in Colorado mountains Dozens of avalanches reported in Colorado mountains
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected

1.30M Followers Like
311 Followers Pin
766 Followers Follow

Latest News

Joke’s on Tottenham again but relegation might be the punchline
Sports February 23, 2026
TSA Says PreCheck Still Operational After Previous Announcement Of Suspension During Funding Fight
TSA Says PreCheck Still Operational After Previous Announcement Of Suspension During Funding Fight
World News February 23, 2026
Wells Fargo Raises its Price Target on The Clorox Company (CLX) to $125 and Maintains an Equal Weight Rating
Wells Fargo Raises its Price Target on The Clorox Company (CLX) to $125 and Maintains an Equal Weight Rating
Finance February 23, 2026
Edeline Lee Fall 2026 Ready-to-Wear Collection
Fashion February 23, 2026
Lake Lugano Promenade In Switzerland
This Gorgeous Swiss Lake Town Is One Of The Most Underrated Destinations In Europe
Travel February 23, 2026
//

This is your World, Finance, Fitness, Fashion  Sports  website. We provide the latest breaking news straight from the News industry.

Quick Link

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Sitemap

Top Categories

  • Fashion
  • Finance
  • Fitness
  • Gadgets
  • Travel

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!


24x7Report24x7Report
Follow US

Copyright © 2025 Adways VC India Private Limited

Welcome Back!

Sign in to your account

Lost your password?